Objective: To determine the cost-effectiveness of 2 different vascular access strategies among incident dialysis patients. Background: Vascular access is a principal cause of morbidity and cost in hemodialysis patients. Recent guidelines and initiatives are intended to increase the proportion of patients with a fistula. However, there is growing awareness of the high prevalence of fistula failures and attendant complications. Methods: A decision analysis using a Markov model was implemented to compare 2 different vascular access strategies among incident dialysis patients: (1) placing an arteriovenous fistula (AVF1st) as the initial access followed by a synthetic vascular access if the AVF did not mature compared to (2) placing a synthetic vascular access (SVA1st) as the initial access device. The cost-utility was evaluated across a range of the risk of complications from temporary catheters and SVA. Results: Under base case assumptions, the AVF1st strategy yielded 2.19 quality-adjusted life years (QALYs) compared with 2.06 QALYs from the SVA1st strategy. The incremental cost-effectiveness was $9389 per QALY for AVF1st compared to SVA1st and was less than $50,000 per QALY as long as the probability of maturation is 36% or greater. AVF1st was the dominant strategy when the AVF maturation rate was 69% or greater.
V ascular access costs for hemodialysis (HD) are high, and their complications have been associated with as 10% to 15% of all inpatient stays among HD patients. 1 Arteriovenous fistulas (AVFs) are the preferred vascular access for HD. 2 Mature AVFs require many fewer interventions to maintain their long-term patency than do arteriovenous grafts 3 and have been associated with a survival advantage. 4, 5 Disadvantages of AVFs include the inability to be used in the acute setting because of the time needed for their full maturation is 3 to 4 months. Fistula maturation indicates dilatation, augmented blood flow, and vessel wall thickening sufficient for use in HD. The probability of maturation is difficult to predict with up to 60% of AVFs failing to mature adequately. [6] [7] [8] [9] [10] [11] [12] As a result of these attributes of AVFs and the common need for dialytic therapy by the time an AVF is placed, temporary catheter placement frequently occurs at the time of AVF surgical construction. Indeed, the large proportion of endstage renal disease (ESRD) patients who require dialysis at the time of initial clinical presentation has been cited as a partial explanation for the predominance of synthetic vascular access. 13, 14 Approximately, 40% of patients present to the nephrologist 3 or fewer months before needing dialysis treatment, making it difficult to establish a mature AVF before initiation of chronic dialysis treatments. 13 Synthetic vascular accesses (SVA) are frequently placed in patients who fail AVF placement or in whom rapid availability of vascular access is desired, because they can be used 1 to 2 weeks after placement. Synthetic vascular accesses have higher failure/complication rates than those associated with AVFs due primarily to the development of stenosis at the venous anastomosis resulting from intimal hyperplasia.
The reported cumulative patency rates of synthetic vascular access are 42% to 60% at 3 years compared with 80% for maturing AVFs. 15, 16 The complication rate for AVF is at least 5 times lower that for synthetic grafts. 9, 17 In 1997, The National Kidney Foundation published the Dialysis Outcome and Quality Initiative (DOQI), which included the goal of increasing the use of AVF as new accesses are placed. 18 This was followed by the KDOQI vascular access guidelines and a Centers for Medicare and Medicaid Services initiative (Fistula First) to increase the proportion of patients who undergo dialysis with a fistula to 66%. 19, 20 Competing issues contribute to the decision about which HD vascular access strategy to pursue. SVAs can be cannulated and used for HD much sooner than AVFs, greatly reducing the exposure to central venous catheter complications, a benefit of SVAs at least partially offset by their higher rate of complications and failure. We undertook a decision analysis using a Markov model to examine the factors influencing the risk-reward balance between AVFs and SVAs as the initial approach to vascular access placement.
METHODS

Model Design
A state-transition Markov model was constructed to compare 2 potential vascular access management strategies: synthetic vascular access as the initial vascular access (SVA1st) versus AVF as the initial vascular access backed by synthetic vascular access (AVF1st). Using a Markov model, a mathematical simulation in which patients move among various states of health and disease over time, 21, 22 permits examination of various treatment options on health state transitions and net treatment effects measurable in terms of both health outcomes and costs. In addition, each potential health state outcome can be modified by its value or utility. The source and value of probabilities of different clinical outcomes for each decision strategy are presented in Table 1 . Hypothetical patients were transitioned through the different health states in cycles 1 year in duration. The model was fit across a total of 5 years. Costs were examined in dollars and effects in quality-adjusted life years (QALY). Costs were evaluated from the perspective Medicare the primary payer for 85% of HD patients during the study period. 23 Therefore, all payments made by Medicare are easily identified and represent national data. An annual discount rate of 3% was incorporated into the models.
Under the SVA1st strategy, 5 possible clinical states were assumed: (1) uncomplicated synthetic vascular access, (2) an infective episode resolved with medical management, (3) an occlusive event resolved with medical management, (4) abandonment of access due to infection of thrombotic complication requiring a new access, or (5) death. In our model, patients could transition to any of the other clinical states during the next transition period according to the assumed probabilities of change between one state and another (Fig. 1) . For example, subjects could progress from an episode of thrombosis that required intervention to a no complication state the following cycle.
Under the AVF1st strategy, an initial maturation probability of AVF was defined. If the AVF matured, it could remain patent with or without intervention. Only 1 AVF was placed in an individual. If the AVF failed to mature after 12 weeks, the patient were assumed to undergo SVA placement with subsequent health transitions occurring analogous to those experienced by patients receiving an SVA as their initial access (SVA1st). The need for longer periods of temporary catheter use and a second surgical procedure were incorporated into the decision tree. Death was an absorbing state.
The following assumptions were incorporated into the decision models:
1. Patients had temporary dialysis catheters in place, on average, for 2 weeks after SVA placement and for 12 weeks after AVF placement. 2. Patients may have had one access complication per yearlong cycle. 3. The probability of an access complication was 20% higher among subjects who experienced a prior complication. 4. Catheters and the vascular access were placed at the same time. 5. Vascular access placement was guided by venous mapping. 6. If an AVF failed, a synthetic vascular access was placed during the same cycle.
The decision model was developed using DATA 3.5 (TreeAge Software, Inc. Williamstown, MA).
SUMMARY OF AVAILABLE DATA Probabilities of Events
The probabilities of events were obtained from a review of the English language literature in MEDLINE from 1966 to 2008 using keywords: vascular access, polytetrafluoroethylene, arteriovenous fistula, HD, and temporary catheters. Data were included only from original articles written in English describing research in humans. Articles were excluded if AVF and SVA were not examined separately. Table 1 includes a summary of the probabilities used for AVF and SVA in this decision analysis.
Utility Measures
There are no published data on the reduction in quality of life associated with vascular access complications. Therefore, we obtained and estimated the magnitude of these reductions by asking individuals undergoing HD to score complications from all types of vascular access using a Likert scale. An interval scale was constructed in which optimal health in an ESRD patient with a functional HD access was assigned a value of 10 and death a value of 0. All utilities assigned were divided by 10 and used in the modeling process to generate quality-adjusted survival data. The disutility of an access complication was applied only to the cycle in which the patient had the complication. Therefore, a patient who experienced a complication during one cycle could have a different utility score for the following cycle. In a sensitivity analysis, this utility measure was varied, specifically, first doubled and then halved ( Table 2) . †Adjusted hospital cost = 1 / 2 outpatient + 1 / 2 inpatient costs.
Costs
Direct costs for access placement included costs of physician and hospital care. Costs of complications such as infected grafts, revision, and thrombectomy were based on Medicare payments to hospitals and physicians for the relevant diagnosis-related group (DRG) and current procedural terminology (CPT). The frequencies and costs of hospitalization secondary to vascular procedures during 2004 were obtained from Centers for Medicare & Medicaid Services. Institutional inpatient and outpatient costs were taken from USRDS 13 and adjusted to 2004 dollars. All pertinent DRG; International Classification of Diseases, Ninth Revision; and CPT codes are listed in Table  3 . When there was more than one possible code for a procedure, a weighted average was used to derive the cost for that procedure.
For example, the cost of replacement of an infected SVA was estimated to be the cost of the SVA excision added to the cost of a femoral line placement for HD at the time the infection was recognized, the cost of placement, and use of a dialysis catheter for 2 weeks, a course of antibiotic treatment for 2 weeks, and the cost of a new SVA placement including anesthesia costs. These costs summed to $14,506.
Costs of catheter complications for 2 weeks were assumed to be those associated with placement, and catheter complications such as thrombosis and infection (bacteremia and septicemia). The average cost of placing AVFs and SVAs was the average cost of any such procedure at any site. For example, to estimate costs for AVFs, codes 36821 (Cimino type), 36825 (autogenous graft), 36819 (basilic vein transposition), and 36820 (forearm vein transposition) were included.
Because half the vascular access procedures are performed on an outpatient basis, an adjusted hospital cost was estimated from the average of the hospital outpatient and inpatient costs.
The frequency of use and cost of emergency dialysis through a femoral temporary catheter placed acutely secondary to a nonfunctioning permanent vascular access were estimated from billing data from the inpatient dialysis unit of the University of Pennsylvania Medical Center during a 6-month period (unpublished data).
Sensitivity and Threshold Analyses
We modified all probabilities in 1-and 2-way sensitivity analyses to explore how assumptions built into our base-case estimates influenced the interpretation of our model. In particular, we targeted the impact of utilities, AVF maturation rate, cost of AVF placement, and complication rate of central venous catheters. 
RESULTS
Utilities
Utility questionnaires were completed by 10 HD patients. Five were male and 5 were African American. Their mean age was 54 years. Half had a native arteriovenous fistula at the time they completed the questionnaire. Only 1 was using a central venous catheter as a HD vascular access. Five subjects stated they had never had any episode of infection or thrombosis with their current vascular access whereas 3 stated they had never had an episode of infection or thrombosis with any previous HD vascular access. Results are presented in Table 2 .
Decision Tree
Using our baseline case with a maturation rate of AVF of 66% as this is the goal of the Fistula First program, the cost for the AVF1st strategy was $16,151 compared with $14,930 for the SVA1st strategy. The AVF1st strategy generated a total of 2.19 QALYs compared to 2.06 from the SVA1st strategy. SVA1st strategy had a better costutility ratio [$7248 vs. $7375]. In addition, the incremental costeffectiveness was $9389 for each QALY gained from AVF1st strategy compared to SVA1st strategy. Table 4 depicts the proportion of the cohort in each Markov state at the end of 5 years. The majority of our cohort (70.8%) in either strategy had died. Under the AVF1st strategy, owing to assumed placement of an SVA after AVF failure, 11.9% had a functioning SVA.
Sensitivity and Threshold Analyses
We evaluated the maturation rate at which the AVF1st strategy had (a) a better average cost-utility, (b) was less costly, or (c) produced more QALYs than the SVA1st strategy. The AVF1st strategy had a better average cost-utility than SVA1st as long as the AVF maturation rate was greater than 69% (Figure 2A) . Furthermore, as presented in Figures 2B , the AVF1st strategy became less costly than SVA1st only if the AVF maturation rate was greater than or equal to 82%. In addition, the AVF1st strategy yielded more QALYs if the AVF maturation rate was only 5% or greater. The incremental costeffectiveness ratio (cost/utilities) comparing AVF1st versus SVA1st exceeded $50,000 per QALY for AVF maturation rates of 36% or below. A threshold of $50,000 per QALY has been suggested as the incremental cost-effectiveness ratio below which an intervention is considered cost-effective.
An increase in reimbursement for AVF placement has been suggested as an option to increase placement of AVF. Even if the reimbursement for AVF placement would triple compared to SVA placement, the incremental cost-effectiveness ratio of AVF1st versus SVA1st strategy would only rise from $9389 to $20,000.
Over the years, a larger proportion of HD access placement is done in the outpatient setting and, therefore, the reimbursed hospital costs per procedure have decreased over time. In Figure 3 2-way sensitivity on how changes in AVF maturation rate and adjusted hospital costs, an average of the hospital outpatient and inpatient costs for vascular access, affect which strategy is less costly. Using our base case of AVF maturation rate of 66%, if the adjusted hospital costs were greater than $10,472, the AVF1st strategy would be less costly.
We evaluated the effect of varying utilities on the different strategies. If the utility estimates for all SVA estimates were 50% lower, at any maturation rate, AVF1st yielded more QALYs. If the utility estimates were decreased by 50% for all AVF estimates, at a maturation rate of 50%, the incremental cost-effectiveness ratio fell to less than $50,000 comparing AVF1st to SVA1st.
DISCUSSION
Vascular access failure causes substantial morbidity for patients and high costs for the ESRD program. 1, 15 The National Kidney Foundation's Dialysis Outcome Quality Initiative (DOQI) clinical practice guidelines on vascular access recommend that AVF be the preferred vascular access for chronic hemodialysis patients. 18 The frequent need for immediate dialysis has been cited as a reason for placing SVA in incident dialysis patients. 26, 27 Using our baseline case, the AVF1st strategy generated 0.13 additional QALYs compared to the SVA1st strategy. The incremental cost-effectiveness was $9389 per QALY for AVF1st compared to SVA1st. These findings were not significantly changed by variations in utility values. The AVF1st strategy had a better average cost-utility than SVA1st when the AVF maturation rate was greater than 69%. The rate of maturation would need to be unrealistically high at 82% for AVF1st strategy to be less costly. However, the incremental cost-effectiveness of AVF1st versus SVA1st fell below $50,000 per QALY only when the AVF maturation rate was at or below 36%. In light of the high probability of AVF maturation failure, often reported to be 50% or higher, 10 the AVF1st strategy may be most appropriate only for a subset of HD patients whose risk of AVF maturation failure is relatively low. These findings were stable across a range of assumptions.
Outside of the United States, the majority of HD patients use an AVF as their vascular access. The wide regional variation in type of vascular access suggests AVF utilization could be increased substantially. 17, 28 In 1990, AVF in incident dialysis individuals ranged from a low of only 15% in the southeastern central United States to a high of 77% in New England (P < 0.0001). Therefore, a great majority of patients undergo synthetic vascular access placement despite the fact that a many may have been able to undergo successful placement of an AVF. Despite national practice guidelines, a recent national study reveals the same geographic variability in AVF placement along with known gender and racial disparities. 28 The reasons for use of SVA as the first access placed in HD patients are unclear, but it may include increased reimbursement for SVA placement compared to AVF, decreased availability of surgeons with expertise for AVF placement, 29 and ease of placement of SVA compared to AVF. 30 Our estimates are very conservative in that assumptions favored the use of SVA. We assumed that all SVA that were placed were functional. Initial successful placement of an SVA has been estimated to be between 90% and 98% 8, 31, 32 with primary unassisted patency at 1 year of 23%. 33 We allowed for the placement of only 1 AVF per patient in our model. Several recent reports suggest that AVFs that do not mature initially may be salvaged after a combination of angioplasty and accessory vein ligation. 34 Others suggest the use of vein transposition, 35 using upper arm brachiocephalic or brachiobasilic fistulas in an effort to increase the number of AVFs in the HD population. In addition, maturation rates of 97.5% have been reported using 3 major surgical approaches according to the preoperative evaluation: forearm AVF, perforating vein fistula at the elbow, and nonperforating vein fistula at the elbow. 36 We also only allowed 1 complication per cycle. We did not include costs of performing procedures in nonthrombosed SVA detected by flow monitoring devices, which would increase the cost of SVA.
In our base model, AVF 1st strategy meets the $50,000 per QALY threshold as long as the probability of maturation is 36% or greater. This rate of maturation of AVF is similar to some described in the literature and is not always easy to predict in an individual patient. Therefore, there is a need for diagnostic tests and predictive rules that will provide risk stratification of AVF maturation.
A functioning AVF is associated with patient survival. AVF use 90 days after dialysis initiation is associated with lower cardiovascular mortality. 37 Several authors have demonstrated that increasing the use of AVF in incident dialysis patients is possible in the United States. 38, 39 Gibson et al, 39 with the adoption of a multidisciplinary approach, increased their AVF placements from 41.3% to 73.7% during a 7-year period. A recent economic analysis found that the use of AVF according to Fistula First Program's goal would prolong survival of the average patient by an estimated 0.38 years. 40 Our study has several limitations including the possibility that our assumptions were not a depiction of the "real world". However, we used sensitivity analyses to examine the influence of assumptions regarding the impact of utilities, AVF maturation rate, cost of AVF placement, and complication rate of central venous catheters on our decision model. As with many Markov models, ours also incorporated the assumption that the probability of moving from one state to another is independent of the history of the individual before arriving in that state. We addressed this in the model by increasing the probability of a future SVA complication by 20% if a complication had occurred in the previous cycle. There is no published information on patient utilities for HD vascular access. Therefore, utilities for the different types of vascular access procedures were directly measured in a small group of patients. However, sensitivity analysis showed that even under extreme assumptions regarding high SVA utilities, the AVF1st strategy was more cost-effective if the maturation probability was greater than 50%.
CONCLUSIONS
The incremental cost-effectiveness of AVF 1st versus SVA 1st strategies was less than $50,000 per QALY as long as the probability of AVF maturation was set at 36% or greater. Given the observation from recent trials that the average AVF maturation rate is very close to this threshold figure, 10 the current emphasis of placing AVFs in all dialysis patients may not be optimal. Initiatives to develop better predictive models of AVF maturation that would permit stratification of patients with regard to their probability of fistula maturation are now underway at the National Institutes of Health and promise to provide tools enabling more targeted use of fistulas to optimize clinical outcomes.
